Skip To Main Content

Dyslipidemi

Understanding Cardiovascular Risk and Prevention: Insights from Professor Pasquale Perrone-Filardi

Understanding Cardiovascular Risk and Prevention: Insights from Professor Pasquale Perrone-Filardi

Preventive Cardiology: Key Insights from Professor Michal Vrablik

Preventive Cardiology: Key Insights from Professor Michal Vrablik

A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I

A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I

Roth Eli M et al. Atherosclerosis vol. 254 (2016): 254-262

Why Don’t We Strike Early, Strike Strong?

Why Don’t We Strike Early, Strike Strong?

Prof. Dr. Halvorsen, Prof. Dr. Sinnaeve & Prof. Dr. Martens